Kiniksa Pharmaceuticals International, plc $KNSA Position Increased by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP has increased its stake in Kiniksa Pharmaceuticals International by 30.4% in Q1, now owning 91,032 shares valued at approximately $2.02 million.
• Recent analysts' ratings show a positive outlook for Kiniksa, with Wells Fargo raising its price target from $30 to $42, while Jefferies Financial Group increased its target from $45 to $54.
• Insider selling was reported, with CFO Mark Ragosa and COO Eben Tessari both reducing their shareholdings significantly, indicating a 41.15% and 28.72% decrease in their ownership, respectively.

Wellington Management Group LLP raised its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 30.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 91,032 shares of the company's stock after buying an additional 21,219 shares during the quarter. Wellington Management Group LLP owned about 0.13% of Kiniksa Pharmaceuticals International worth $2,022,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Wells Fargo & Company MN lifted its holdings in Kiniksa Pharmaceuticals International by 54.7% during the fourth quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock valued at $417,000 after purchasing an additional 7,463 shares during the last quarter. Barclays PLC grew its stake in shares of Kiniksa Pharmaceuticals International by 11.2% during the 4th quarter. Barclays PLC now owns 71,896 shares of the company's stock valued at $1,423,000 after acquiring an additional 7,267 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Kiniksa Pharmaceuticals International by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after acquiring an additional 29,300 shares during the period. MetLife Investment Management LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after acquiring an additional 1,374 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in shares of Kiniksa Pharmaceuticals International by 117.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after acquiring an additional 4,575 shares during the period. Institutional investors own 53.95% of the company's stock.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, Director Thomas Malley sold 78,233 shares of the stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the transaction, the director owned 12,546 shares in the company, valued at approximately $415,147.14. This represents a 86.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John F. Paolini sold 29,325 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total value of $954,528.75. Following the completion of the sale, the insider directly owned 57,403 shares of the company's stock, valued at $1,868,467.65. This represents a 33.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 558,403 shares of company stock worth $18,078,671 over the last quarter. 53.48% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on KNSA. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Wells Fargo & Company upped their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 30th. Finally, Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA traded down $0.24 during midday trading on Thursday, reaching $35.24. 192,022 shares of the company's stock were exchanged, compared to its average volume of 672,115. The firm's 50 day simple moving average is $30.65 and its two-hundred day simple moving average is $26.27. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of 882.35 and a beta of 0.20. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $35.59.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The firm had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.